Cardiff Oncology (CRDF, Financial) has successfully obtained a new U.S. patent, No. 12,263,173, from the United States Patent and Trademark Office. This patent encompasses the innovative method of using onvansertib in combination with bevacizumab to treat metastatic colorectal cancer patients who have not been previously treated with bevacizumab. The patent is projected to remain in effect until at least 2043.
The company shared initial findings from their ongoing CRDF-004 clinical trial in December 2024. They anticipate releasing further clinical trial data in the first half of 2025, which will provide additional insights into the efficacy of this treatment approach.
